16 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 16 Phase 1, 4 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 12, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Not applicable | 2 | Terminated 1, Unknown 1 |
Follow Peptides: new trials by email Literature Review of Peptides trials Research Report on Peptides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Vaccine for TNBC Immunotherapy Peptide (neoantigen) pulsed autologous Dendritic cell - Breast Cancer Female | Phase 1 | Not yet recruiting | Universidad Nacional de Colombia | 8 | 2025-08-01 | 2025-06-25 |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab - Biliary Tract Cancers | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 25 | 2025-05-27 | 2026-05-08 |
| Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis. Polypeptides, Femoral-popliteal bypass grafting with a synthetic graft above the knee, Routine conservative treatment - Peripheral Arterial Occlusive Disease | Not applicable | Unknown | Ryazan State Medical University | 120 | 2023-04-01 | 2023-07-06 |
| Evaluation of the Effect of Self-Assembling Peptide P11-4 Peptide - Dental Caries | Phase 1 | Completed | Egymedicalpedia | 30 | 2021-07-01 | 2023-01-06 |
| A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma Peptide, Anti-PD-1, rhGM-CSF - Melanoma (Skin) | Phase 1 | Unknown | Xiangya Hospital of Central South University | 30 | 2020-04-21 | 2020-04-28 |
| Phase 1A Study of the Safety of KSP/QRH Dimer KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg, KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg - Healthy Adults | Phase 1 | Completed | University of Michigan | 26 | 2018-08-22 | 2018-11-06 |
| Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma Poly-ICLC, Tumor Treating Fields, Peptides - Glioblastoma | Phase 1 | Active not recruiting | Adilia Hormigo | 13 | 2018-03-01 | 2026-09-21 |
| Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines Peptides - The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data | Completed | Queen Mary University of London | 192 | 2016-09-01 | 2022-09-22 | |
| Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Fimaporfin (Photosensitizer), Hiltonol (Poly-ICLC), HPV E7 (Human Papilloma Virus E7) peptides - Healthy Volunteer | Phase 1 | Completed | PCI Biotech AS | 96 | 2016-09-01 | 2019-08-28 |
| Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies Peptides, Poly-ICLC, Lenalidomide - Solid Tumors | Phase 1 | Completed | Nina Bhardwaj | 13 | 2016-04-01 | 2021-01-11 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma Poly-ICLC, Peptides - Melanoma | Phase 1 | Completed | Patrick Ott, MD, PhD | 15 | 2014-04-01 | 2025-12-29 |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 73 | 2010-08-13 | 2023-07-19 |
| Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 CP 870,893, Peptides, Oncovir poly IC:LC - Melanoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2009-10-01 | 2015-09-24 |
| Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection peptide vaccine (AFO-18) - HIV INFECTIONS | Phase 1 | Completed | Gitte Kronborg | 11 | 2009-09-01 | 2014-03-27 |
| Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide - Melanoma, Skin Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2008-12-01 | 2015-10-28 |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer peptide - Esophageal Cancer | Phase 2 | Unknown | University of Yamanashi | 60 | 2008-11-01 | 2009-10-15 |
| Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Autologous dendritic cell-adenovirus CCL21 vaccine - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 13 | 2008-11-01 | 2012-09-24 |
| Sublingual Immunotherapy for Food Allergy Food Drops: Food Allergens (peptides) - Food Allergies | Not applicable | Terminated | University of Missouri-Columbia | 31 | 2008-10-01 | 2016-06-17 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim) - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2007-06-01 | 2021-07-12 |
| Melanoma Vaccine With Peptides and Leuprolide Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide - Melanoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 98 | 2005-11-01 | 2019-10-16 |
Showing 20 of 23. Sign in to see all of them.
Melanoma (9) · Neoplasms (2) · Skin Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma (1) · Dental Caries (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Neoplasms (1) · Eye Neoplasms (1) · Food Hypersensitivity (1) · Glioblastoma (1) · HIV Infections (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · National Cancer Institute (NCI) (2) · Adilia Hormigo (1) · Dr. Nina Bhardwaj (1) · Egymedicalpedia (1) · Gitte Kronborg (1) · M.D. Anderson Cancer Center (1) · Malaria Vaccine and Drug Development Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Nina Bhardwaj (1) · PCI Biotech AS (1) · Patrick Ott, MD, PhD (1) · Queen Mary University of London (1) · Ryazan State Medical University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (14) · Colombia (2) · United Kingdom (2) · China (1) · Denmark (1) · Egypt (1) · Japan (1) · Russia (1)
Nina Bhardwaj, MD, PhD (2) · Adilia Hormigo, MD, PhD (1) · Anders Fomsgaard, MD (1) · Asmaa Mosleh, Lecturer (1) · Deepa Chandhrasekhar, BS (1) · Gitte Kronborg, MD (1) · Igor Suchkov (1) · Jan Gerstoft, MD (1) · Jeffrey S. Weber, MD, PhD (1) · Jeffrey Weber, M.D., Ph.D. (1) · Jim Bush, MBChB, PhD, MRCS, MFPM (1) · Koji Kono, MD.PhD (1) · Marina Baretti, MD (1) · Minocher Battiwalla, MD (1) · Myriam Arevalo-Herrera, PhD (1)
PMID 21134985, PMID 22776426, PMID 23314272, PMID 23861247, PMID 28678778, PMID 28678784, PMID 33479501, PMID 33488576, PMID 34311780, PMID 36450385
2008 (1), R21CA099265 (1)